Sertraline updated on 07-01-2025

Craniosynostosis

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7468
R22192		 Anderson, 2020 Craniosynostosis 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.91 [1.31;2.77] -/-   0/- - -
ref
S5398
R14863		 Bérard (Controls exposed to non-Sertraline SSRI), 2015 Craniosynostosis 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.85 [0.25;2.87] C
excluded (control group) 		3/366   19/1,963 22 366
ref
S6705
R18935		 Bérard (Controls unexposed, sick), 2015 Craniosynostosis 1st trimester retrospective cohort (claims database) unexposed, sick Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) 2.03 [1.09;3.75] 3/366   63/14,868 66 366
ref
S6008
R15434		 Furu, 2015 Craniosynostosis 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.30 [0.58;2.93] 7/7,245   1,210/2,266,875 1,217 7,245
ref
S7352
R21536		 Wemakor, 2015 Craniosynostosis 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 3.98 [0.52;30.40] C 1/15   306/17,375 307 15
ref
S6244
R16528		 Malm, 2011 Craniocynostosis 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: no or not specified 2.42 [0.33;17.60] -/869   -/628,607 - 869
ref
S6159
R16149		 Louik, 2007 Craniosynostosis 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.80 [0.20;14.90] 1/47   114/5,928 115 47
ref
Total 6 studies 1.88 [1.41;2.51] 1,705 8,542
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson, 2020Anderson, 2020 1.91[1.31; 2.77]--60%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Bérard (Controls unexposed, sick), 2015Bérard, 2015 1 2.03[1.09; 3.75]6636622%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Furu, 2015Furu, 2015 1.30[0.58; 2.93]1,2177,24513%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Wemakor, 2015Wemakor, 2015 3.98[0.52; 30.40]307152%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Malm, 2011Malm, 2011 2.42[0.33; 17.60]-8692%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Louik, 2007Louik, 2007 1.80[0.20; 14.90]115472%ROB confusion: moderateROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Total (6 studies) I2 = 0% 1.88[1.41; 2.51]1,7058,5420.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.76[1.09; 2.83]1,2838,4800%NABérard (Controls unexposed, sick), 2015 Furu, 2015 Malm, 2011 3 case control studiescase control studies 1.95[1.36; 2.81]422620%NAAnderson, 2020 Wemakor, 2015 Louik, 2007 3 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.84[1.33; 2.55]1,6398,1760%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 Malm, 2011 Louik, 2007 5 unexposed, sickunexposed, sick 2.03[1.09; 3.77]66366 -NABérard (Controls unexposed, sick), 2015 1 Tags Adjustment   - No  - No 3.98[0.52; 30.40]30715 -NAWemakor, 2015 1   - Yes  - Yes 1.85[1.38; 2.48]1,3988,5270%NAAnderson, 2020 Bérard (Controls unexposed, sick), 2015 Furu, 2015 Malm, 2011 Louik, 2007 5 Monotherapy   - no or not specified  - no or not specified 2.42[0.33; 17.67]-869 -NAMalm, 2011 1   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.87[1.39; 2.51]1,5907,6260%NAAnderson, 2020 Bérard (Controls unexposed, sick), 2015 Furu, 2015 Wemakor, 2015 4   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.80[0.21; 15.54]11547 -NALouik, 2007 1 Unexposed sick   - intermediate history of illness/tre ...  - intermediate history of illness/treatment (3-12 months before pregnancy) 2.03[1.09; 3.77]66366 -NABérard (Controls unexposed, sick), 2015 1 All studiesAll studies 1.88[1.41; 2.51]1,7058,5420%NAAnderson, 2020 Bérard (Controls unexposed, sick), 2015 Furu, 2015 Wemakor, 2015 Malm, 2011 Louik, 2007 60.510.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-2.63.21.3200.000Anderson, 2020Bérard (Controls unexposed, sick), 2015Furu, 2015Wemakor, 2015Malm, 2011Louik, 2007

Asymetry test p-value = 0.6645 (by Egger's regression)

slope=0.5717 (0.1523); intercept=0.1973 (0.4220); t=0.4674; p=0.6645

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 5398

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.84[1.33; 2.55]1,6398,1760%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 Malm, 2011 Louik, 2007 5 unexposed, sick controlsunexposed, sick controls 2.03[1.09; 3.77]66366 -NABérard (Controls unexposed, sick), 2015 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.85[0.25; 2.87]22366 -NABérard (Controls exposed to non-Sertraline SSRI), 2015 10.510.01.0